These included ad libitum energy intake, ratings of appetite, thirst, nausea, well-being, control of eating, food preference, resting metabolic rate, body weight, and body composition
Laboratory and early clinical studies suggest that GLP-1 receptor agonists may dampen reward-driven behavior and reduce the salience of addictive stimuli
Most side effects remain manageable with appropriate dosing and monitoring
As of now, the FDA has set deadlines for compounders to stop producing tirzepatide products, but it is not enforcing the deadlines at the moment as the lawsuit is ongoing
How much weight do people lose on each The figures most often quoted side by side come from two different trials, in different patient groups, over different time periods